A case series of five hypertensive type 2 diabetes patients showing reduction in blood pressure and mean arterial pressure reduction in ambulatory blood pressure monitoring with remogliflozin etabonate 200 mg coprescribed with recent onset anti-hypertensive drugs

Abstract

Introduction. Hypertension is commonly occurring in type 2 diabetes and metabolic syndrome and inflammation are a well-known part of this disease entity. The data of using remogliflozin in Indian patient is not known as this is a very recently approved molecule for the treatment of type 2 diabetes. Here we look into a case series of five patients who had their ambulatory blood pressure monitoring (ABPM) done at baseline and again after 14 days of therapy of adding remogliflozin etabonate to recent onset antihypertensive druges. Methods. We analysed the ABPM results of five patients after taking their informed consent at baseline and two weeks post-treatment initiation with remogliflozin alongside with recent onset antihypertensive drugs. We used paired t test for statistical analysis of the two readings of each patient to come to a conclusion. Results. We found a statistically significant decrease in mean arterial pressure (MAP) reflected by a p value of 0.0277 and the reduction in mean awake time systolic blood pressure (SBP) was also very close to statistical significance as seen by the p value of 0.0541. Conclusions. Remogliflozin etabonate when co-prescribed with antihypertensive drugs shows a significant reduction in MAP as well as reduction in SBP although most of the contribution seems to be coming from the antihypertensive molecule itself.